PT  - JOURNAL ARTICLE
AU  - Danielle Korkus
AU  - Tal Gazitt
AU  - Arnon Dov  Cohen
AU  - Ilan Feldhamer
AU  - Idit Lavi
AU  - Amir Haddad
AU  - Sari Greenberg-Dotan
AU  - Erez Batat
AU  - Devy Zisman
TI  - Increased prevalence of Lupus Co-morbidity in Patients with Psoriatic Arthritis: A Population-Based Case-Controlled Study
AID  - 10.3899/jrheum.190940
DP  - 2020 May 15
TA  - The Journal of Rheumatology
PG  - jrheum.190940
4099  - http://www.jrheum.org/content/early/2020/05/09/jrheum.190940.short
4100  - http://www.jrheum.org/content/early/2020/05/09/jrheum.190940.full
AB  - Objective To assess the prevalence of lupus (SLE) in a psoriatic arthritis (PsA) cohort and to compare it to the general population using the database of a large health care provider. Methods We analyzed the database of the PsA cohort (2002-2017) matched for age and sex with randomly selected controls for demographics, clinical and laboratory manifestations and dispensed medications. Statistical analysis used student’s t-test, Chi square test, as appropriate. In the PsA group, incidence density sampling was performed matching PsA patients without SLE as controls to each case of PsA with SLE by age and follow-up time. Univariable and multivariable conditional logistic regression analysis were used to assess factors affecting SLE development. Results The PsA and control groups consisted of 4836 and 24180 subjects, respectively, median age of 56±15 years, 53.8% of whom were female. Eighteen patients (0.37%) in the PsA group and 36 patients (0.15%) in the control group were diagnosed with SLE (p=0.001). SLE patients without PsA had higher anti-dsDNA and anti-cardiolipin antibodies. Usage of drugs with known potential to induce SLE was higher in the PsA than in the control group. Older age at PsA diagnosis, shorter PsA duration and statin treatment were associated with SLE in PsA patients. Conclusion A 2.3fold increase in the prevalence of SLE in PsA relative to control group was found. Risk factors for SLE development included older age at PsA diagnosis, shorter PsA duration, and statin treatment. The association between PsA and SLE may affect treatment choices and medication development.